Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Aniracetam and CDP-Choline (Citicoline) — mechanism, side effects, legal status, and pricing.
Aniracetam is a non-peptide pyrrolidinone derivative and positive allosteric modulator of AMPA-type glutamate receptors. It is marketed as a prescription drug for cognitive disorders in some European countries (Italy, Greece) but has never been approved by the US FDA as either a drug or dietary supplement ingredient. The compound was reportedly withdrawn from the Japanese market following a failed confirmatory trial. Despite lacking US regulatory approval, aniracetam is openly sold online by nootropic-supplement retailers, often with significant label-accuracy problems.
CDP-choline (citicoline) is a non-peptide cytidine nucleotide-choline conjugate that serves as an intermediate in phosphatidylcholine biosynthesis. It is approved as a prescription drug for stroke and cognitive disorders in Japan and parts of Europe but sold only as a dietary supplement ingredient in the United States, where it is not FDA-approved as a drug. Human evidence is mixed and indication-dependent: small trials report modest memory improvements in healthy/older adults, but the largest phase 3 RCT (COBRIT, n=1,213 traumatic brain injury patients) found no benefit over placebo.
Aniracetam
CDP-Choline (Citicoline)
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Aniracetam
No pricing data yet.
Check Aniracetam prices →CDP-Choline (Citicoline)
No pricing data yet.
Check CDP-Choline (Citicoline) prices →COA corpus from Disclosed Labs — independently tested batches only.
Aniracetam
2
COAs
99.5%
Avg purity
2
Labs
CDP-Choline (Citicoline)
No COA data yet.
Submit testing data →The principal human efficacy evidence is one 6-month, double-blind, placebo-controlled multicenter trial in 109 elderly patients meeting probable-Alzheimer's criteria, which showed significant improvement in psychobehavioral parameters versus placebo with excellent reported tolerability, though no itemized adverse-event breakdown was available. No long-term (multi-year) human safety data were located, and no interventional trials of aniracetam are currently registered on ClinicalTrials.gov. In rodent models, aniracetam (50 mg/kg/day for 10 postnatal days) reversed prenatal-ethanol-induced avoidance-learning deficits in rat offspring and increased AMPA-receptor-mediated synaptic currents in hippocampal CA1 pyramidal cells. However, oral aniracetam (50 mg/kg, 5 days/week for 6 weeks) produced no cognitive or behavioral enhancement in healthy adult C57BL/6J mice across a comprehensive test battery.
Key references
Human evidence is mixed and indication-dependent. Small-to-moderate placebo-controlled RCTs in healthy/older adults and age-associated memory impairment report modest verbal/episodic memory improvements at ~500–1,000 mg/day over weeks to months. However, the largest trial to date—COBRIT, a phase 3 double-blind placebo-controlled RCT in 1,213 traumatic brain injury patients—found no benefit over placebo on functional or cognitive outcomes (GOS-E favorable outcome 35.4% citicoline vs 35.6% placebo; global OR 0.98, 95% CI 0.83–1.15). Evidence for Alzheimer's disease and MCI is described in reviews as insufficient and inconsistent. In preclinical models, aged rats with hippocampal damage showed reduced long-term memory impairment with dietary CDP-choline supplementation, and mice subjected to ischemic stroke showed SIRT1-dependent reduction in cerebral infarct volume.
Aniracetam and CDP-Choline (Citicoline) are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs